Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1541-1546

  Puglisi, Fabio ^a   Cardellino, G G ^a   Crivellari, D ^b   Di Loreto, C ^a   Magri, M D ^b   Minisini, A M ^a   Mansutti, M ^a   Andreetta, C ^a   Russo, S ^a   Lombardi, D ^b   Perin, T ^b   Damante, G ^a   Veronesi, A ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Capecitabine; Docetaxel; Metastatic breast cancer; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; DOCETAXEL; MESSENGER RNA; THYMIDINE PHOSPHORYLASE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HAND FOOT SYNDROME; HEARTBURN; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TAXOIDS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 50849093506     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn165     Document Type: Article

References (21)

1. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine; which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
2. Toi M, Rahman MA, Bando H, Chow L. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158-166.
3. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/ taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
4. Kurosumi M, Tabei T, Suemasu K et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000; 7: 945-948.
5. Toi M, Bando H, Horiguchi S et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Bf J Cancer 2004; 90: 2338-2343.
6. Puglisi F, Andreetta C, Valent F et al. Arithracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18: 883-888.
7. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracypline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
8. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379-1385.
9. Nadella P, Shapiro C, Otterson GA et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20: 2616-2623.
10. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G. Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue. Breast Cancer Res Treat 2004; 86: 215-223.
12. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
13. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group J Clin Oncol 2005; 23: 4265-4274.
14. Puglisi F, Cardoso F. Lebrun F, Piccart M. First-line treatment of metastatic breast cancer: Available evidence and current recommendations, Am J Cancer 2006; 5: 99-110.
15. Mackey JR, Tonkin KS, Kow SL et al. Final results of a phase II clinical trial of weekly docetaxel in combination with Gapecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004; 5: 287-292.
16. Ramanathan RK, Ramalingam S, Egorin MJ et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005; 55: 354-360.
17. Mrozek E, Ramaswamy B, Young D et al. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 2006; 7: 141-145.
18. Gradishar WJ, Meza LA, Amin B et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Ciin Oncol 2004; 22: 2321-2327.
19. Blum JL, Dees EC, Chacko A et al. Phase II trial of capecitabine and weekly pacitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 24: 4384-4390.
20. Blum JL, Dees EC, Vukelja SJ et al. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 2007, 7, 465-470.
21. Gick U, Rochlitz C, Mingrone W et al. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: A phase II report of the SAKK. Oncology 2006; 71: 54-60.